Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

Addition of Ublituximab/Umbralisib to Ibrutinib Produces High uMRD Rate in CLL

May 2nd 2022

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26th 2022

Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.

Treosulfan-Based Conditioning Improves Survival in Elderly, Comorbid Patients With AML

April 15th 2022

Treatment with a treosulfan-based conditioning regimen led to a superior event-free and overall survival compared with busulfan-based conditioning in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation, according to a post-hoc subgroup analysis of the phase 3 MC-FludT.14/L trial.

Pathologic Fractures Linked With Poor Outcomes in Osteosarcoma, Ewing Sarcoma

April 15th 2022

For patients with osteosarcoma or Ewing sarcoma who develop pathologic fractures, the prognosis remains poor; however, there is still the possibility for limb salvage therapy.

Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets

April 13th 2022

The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10th 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Pegcetacoplan Improves Efficacy in Complement Inhibitor–Naïve Paroxysmal Nocturnal Hemoglobinuria

April 9th 2022

Pegcetacoplan treatment was associated with hemoglobin stabilization and normalization, as well as a superior change from baseline in hemoglobin levels, which showed a meaningful correction of anemia, in patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

Checkpoint Blockade Before Allogeneic Transplant Improves PFS, But Not OS, in Hodgkin Lymphoma

April 7th 2022

Checkpoint inhibitors prior to allogeneic hematopoietic cell transplant improved progression-free survival and relapse incidence in patients with Hodgkin lymphoma, but the treatment did not improve non-relapse mortality or overall survival.

Pediatric Patient With Severe TA-TMA Elicits Response to Narsoplimab

March 28th 2022

A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab.

Randall Talks Rich AAOS 2022 Program, Packed With Engaging Discussions

March 28th 2022

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

Axi-Cel Shows Clinically Meaningful Improvement in QOL in Second-Line Relapsed/Refractory LBCL

March 23rd 2022

Axicabtagene ciloleucel demonstrated a clinically improvement in quality of life compared with standard of care chemotherapy in the second-line setting for patients with relapsed/refractory large B-cell lymphoma.

CD34 Selection Process Evolves into Practice-Changing Approaches in Hematologic Cancers

March 21st 2022

Miguel-Angel Perales, MD, discusses the science behind Orca-T and other approaches targeted to improve GVHD relapse-free survival in select patients with hematologic cancers.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

March 20th 2022

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer

March 11th 2022

The FDA has approved olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously received chemotherapy either before or after surgery.

Higher Doses of Ibrutinib/Venetoclax Not Linked With Higher Responses in Relapsed/Refractory MCL

March 8th 2022

The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development

March 4th 2022

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

FDA Approves Pacritinib for Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

FDA Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

March 1st 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.